RxDoctor Payments Data

Dhruvin Mehta, MD

Family Medicine · Newburgh, INNPI 1871023556

Payments from drug & device makers

$6,193in general payments, 2019–2025

Across 421 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$686
  • Pfizer$591
  • GSK$415
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$387
  • Lilly USA, LLC$224
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,13699%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,193 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$111,593
Medicare patients
319
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$90,526
OzempicSemaglutide55$82,266
JardianceEmpagliflozin48$66,999
TrulicityDulaglutide46$58,142
VraylarCariprazine Hcl35$51,062
FarxigaDapagliflozin Propanediol43$43,409
JanuviaSitagliptin Phosphate32$32,429
TradjentaLinagliptin27$24,896
XareltoRivaroxaban27$22,383
MounjaroTirzepatide12$21,482
JanumetSitagliptin Phos/Metformin Hcl11$17,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,453
Breo ElliptaFluticasone/Vilanterol21$8,426
VyvanseLisdexamfetamine Dimesylate16$7,685
Spiriva RespimatTiotropium Bromide14$7,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$54$99,37889 claims
PfizerEliquis$591$90,52689 claims
Novo NordiskOzempic$686$82,26655 claims
Lilly USA, LLCTrulicity, Mounjaro$224$79,62458 claims
AbbVieVraylar, Synthroid$1,690$55,20788 claims
MerckJanuvia, Janumet$173$49,62243 claims
AstraZenecaFarxiga$149$43,40943 claims
GSKTrelegy Ellipta, Breo Ellipta$415$24,87937 claims
Johnson & JohnsonXarelto$41$22,38327 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$84$7,68516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$3,410392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →